A detailed history of Dillon & Associates Inc transactions in Eli Lilly & CO stock. As of the latest transaction made, Dillon & Associates Inc holds 452 shares of LLY stock, worth $353,992. This represents 0.06% of its overall portfolio holdings.

Number of Shares
452
Previous 452 -0.0%
Holding current value
$353,992
Previous $409,000 2.2%
% of portfolio
0.06%
Previous 0.06%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

SELL
$525.19 - $619.13 $9,978 - $11,763
-19 Reduced 4.03%
452 $264,000
Q3 2023

Nov 13, 2023

BUY
$434.7 - $599.3 $8,694 - $11,986
20 Added 4.43%
471 $253,000
Q2 2023

Aug 08, 2023

BUY
$350.74 - $468.98 $158,183 - $211,509
451 New
451 $212,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $744B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Dillon & Associates Inc Portfolio

Follow Dillon & Associates Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dillon & Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Dillon & Associates Inc with notifications on news.